177 related articles for article (PubMed ID: 15516777)
1. Medullary thyroid carcinoma: nationwide Japanese survey of 634 cases in 1996 and 271 cases in 2002.
Kameyama K; Takami H
Endocr J; 2004 Oct; 51(5):453-6. PubMed ID: 15516777
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
Kambouris M; Jackson CE; Feldman GL
Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
[TBL] [Abstract][Full Text] [Related]
3. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
Sansó G; Domené HM; Iorcansky S; Barontini M
Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
[TBL] [Abstract][Full Text] [Related]
4. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
[TBL] [Abstract][Full Text] [Related]
5. Medullary carcinoma of the thyroid gland and the MEN 2 syndromes.
Skinner MA; Wells SA
Semin Pediatr Surg; 1997 Aug; 6(3):134-40. PubMed ID: 9263335
[TBL] [Abstract][Full Text] [Related]
6. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
Romei C; Tacito A; Molinaro E; Agate L; Bottici V; Viola D; Matrone A; Biagini A; Casella F; Ciampi R; Materazzi G; Miccoli P; Torregrossa L; Ugolini C; Basolo F; Vitti P; Elisei R
Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022
[TBL] [Abstract][Full Text] [Related]
7. Medullary thyroid carcinoma and multiple endocrine neoplasia type 2.
Takami H
Endocr Pathol; 2003; 14(2):123-31. PubMed ID: 12858002
[TBL] [Abstract][Full Text] [Related]
8. Clinical manifestations of familial medullary thyroid carcinoma.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):348-50. PubMed ID: 15271414
[TBL] [Abstract][Full Text] [Related]
9. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
10. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
[TBL] [Abstract][Full Text] [Related]
11. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
Lodish MB; Stratakis CA
Expert Rev Anticancer Ther; 2008 Apr; 8(4):625-32. PubMed ID: 18402529
[TBL] [Abstract][Full Text] [Related]
12. A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan.
Iihara M; Yamashita T; Okamoto T; Kanbe M; Yamazaki K; Egawa S; Yamaguchi K; Obara T
Jpn J Clin Oncol; 1997 Jun; 27(3):128-34. PubMed ID: 9255265
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and genetic profile of patients with medullary thyroid cancer treated in the Cancer Centre--Institute of Oncology in Warsaw].
Czetwertyńska M; Kozłowicz-Gudzińska I; Stachlewska-Nasfeter E; Sromek M; Skasko E; Paszko Z
Endokrynol Pol; 2006; 57(4):415-9. PubMed ID: 17006846
[TBL] [Abstract][Full Text] [Related]
14. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
[TBL] [Abstract][Full Text] [Related]
15. [The RET gene in multiple endocrine neoplasia type 2 (MEN 2)].
Ito T; Shirahama S; Ogura K; Yamamoto S; Takami H
Nihon Rinsho; 2004 May; 62(5):883-8. PubMed ID: 15148813
[TBL] [Abstract][Full Text] [Related]
16. [Hereditary medullary thyroid carcinoma--genotype-phenotype characterization].
Frank-Raue K; Heimbach C; Rondot S; Usadel KH; Meng W; Varma C; Fuchs-Hammoser R; Höppner W; Schulze E; Raue F
Dtsch Med Wochenschr; 2003 Sep; 128(39):1998-2002. PubMed ID: 14508694
[TBL] [Abstract][Full Text] [Related]
17. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C
Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299
[TBL] [Abstract][Full Text] [Related]
18. Multiple endocrine neoplasia type 2: 2007 update.
Raue F; Frank-Raue K
Horm Res; 2007; 68 Suppl 5():101-4. PubMed ID: 18174721
[TBL] [Abstract][Full Text] [Related]
19. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
Fink M; Weinhüsel A; Niederle B; Haas OA
Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary.
Klein I; Esik O; Homolya V; Szeri F; Váradi A
J Endocrinol; 2001 Sep; 170(3):661-6. PubMed ID: 11524247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
